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INTRODUCTION
Extrahepatic bile duct (EHD) cancer is an uncommon 
devastating disease. It is more common among Asians, 
and its incidence is approximately between 0.5 to 2 
cases/100000 person-years (1-3). The only curative 
treatment for EHD cancer is surgical resection. Surgery 
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for EHD cancer is complex due to the need for a wide 
surgical field; consequently, comprehensive preoperative 
evaluations of tumor extent, major vessel involvement, 
and remnant liver function, among others, are prerogative 
(2, 4). If curative surgical resection is not possible, 
palliative treatment such as systemic chemotherapy and/
or radiotherapy is recommended over cytoreductive surgery 
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(2). An accurate preoperative imaging assessment is 
critical for the prevention of unnecessary procedures and 
successful R0 resection. Guidelines for EHD cancer that 
have been confirmed by national organizations or expert 
groups are limited because of its low incidence and an 
insufficient amount of evidence from studies. Most of the 
existing guidelines do not focus on EHD cancer only; they 
cover intrahepatic cholangiocarcinoma and EHD cancer or 
gallbladder cancer, which require different staging systems 
and treatment methods, and have different prognoses. 
Although some guidelines cover diagnostic imaging, the 
presented recommendations are general guidelines for 
diagnosis, treatment, and prognosis, and they are not 
concerned with specific technical aspects or diagnostic 
criteria for evaluating EHD cancer (4). Recently, the 
Korean Society of Abdominal Radiology (KSAR) developed 
consensus recommendations on controversial issues 
in abdominal radiology (5-7). South Korea has a high 
incidence of EHD cancer, and consequently, many of the 
KSAR members have gained extensive experience in the 
evaluation of EHD cancer. Hence, the KSAR study group for 
EHD cancer leveraged the pool of experts and developed 
consensus recommendations focused on the imaging-driven 
diagnosis of EHD cancer. Structured reporting forms can 
also visualize the essential characteristics that need to 
be evaluated on imaging, which allow easy and accurate 
communication between multidisciplinary team members 
and straightforward collection and analysis of uniform 
reporting data. Until now, there had been no unanimously 
accepted structured reporting forms for EHD cancer due to 
its complexity; in the few that were suggested, reporting 
categories were descriptive rather than specific (8). The 
KSAR study group for EHD cancer also presented a ready-to-
use structured reporting form for EHD cancer based on its 
consensus recommendations.
MATERIALS AND METHODS
Organization and Overall Workflow of the KSAR Study 
Group for EHD Cancer
The KSAR study group for EHD cancer was composed 
of 13 board-certified abdominal radiologists from eight 
tertiary hospitals in South Korea. All of the radiologists 
were KSAR members, and they were experienced with 
biliary images from CT, MRI, and ultrasonography. Each 
member was assigned to one of four subgroups that 
focused on subjects related to EHD cancer: ‘Nomenclature 
and definition,’ ‘Imaging technique,’ ‘Cancer evaluation,’ 
and ‘Tumor response.’ Each subgroup searched and 
evaluated the references, and they developed and refined 
key questions and statements. The first subgroup was 
tasked with determining appropriate nomenclature and 
definitions, which would be used throughout the consensus 
recommendations. The second subgroup was tasked with 
ascertaining the usefulness and effectiveness of different 
imaging modalities for evaluating EHD cancer. The third 
subgroup focused on the approaches for evaluating EHD 
cancer using imaging studies, while the last subgroup was 
tasked with developing guidelines on tumor response after 
treatment. Key questions and statements were developed 
through discussions that took place within each study 
group and between the subgroups.
Literature Search
We searched for reference articles using Medline 
(PubMed). Literature searches were carried out by a 
radiologist and a subject specialist librarian. Before 
performing the literature search, we classified the candidate 
issues into four sections, which were nomenclature and 
definition, imaging technique, cancer evaluation, and 
tumor response. One to five members were assigned to 
each section as investigators, and they performed the 
literature review, developed key questions and statements, 
analyzed the voting results, and wrote a draft of consensus 
recommendations for their assigned sections. Because 
various terms have been used for EHD cancer, a sensitive 
search query was developed to ensure that no relevant 
articles were missed. The search query used (“Klatskin 
Tumor”[Mesh]) OR (Hilar Cholangiocarcinoma*[TIAB] 
OR Perihilar Cholangiocarcinoma*[TIAB] OR Klatskin 
Tumor*[TIAB]) OR (“Common Bile Duct Neoplasms”[Mesh]) 
OR (((“Common bile duct”[TIAB] OR “Common hepatic 
duct”[TIAB]) AND (cancer[TIAB] OR Neoplasm*[TIAB] OR 
Carcinoma*[TIAB] OR Cholangiocarcinoma*[TIAB])) OR 
“CBD-cancer”[TIAB]) OR (“Bile Ducts, Extrahepatic”[Mesh] 
AND “Bile Duct Neoplasms”[Mesh]) OR ((Extrahepatic[TIAB] 
OR Extra-hepatic[TIAB]) AND (“Bile duct”[TIAB] OR “Bile 
ducts”[TIAB]) AND (cancer[TIAB] OR Neoplasm*[TIAB] 
OR Carcinoma*[TIAB] OR Cholangiocarcinoma*[TIAB])). 
After searching 10420 eligible articles for patients with 
EHD cancer, additional literature searches were done for 
the four specific sections. The specific search queries are 
summarized in Supplementary Table 1. We found 2026 
eligible articles: nomenclature and definition (n = 277), 
43
Consensus Recommendations for Extrahepatic Bile Duct Cancer
https://doi.org/10.3348/kjr.2019.0803kjronline.org
imaging technique (n = 1092), cancer evaluation (n = 
416), and tumor response (n = 241). All investigators of 
the KSAR study group for EHD cancer assessed potentially 
relevant articles for eligibility. The decision to include or 
exclude a study was hierarchical, and it was initially based 
on the study title, followed by the abstract and finally the 
complete manuscript. 
Drafting Key Questions and Statements and Initial 
Presentation
In each section, key questions essential to the imaging 
evaluation of EHD cancer were developed, and the assigned 
members brainstormed for all possible recommendations for 
each key question. Initially, 64 recommendation statements 
were developed, and they were presented at the annual 
KSAR meeting on April 26, 2019, with approximately 120 
participating KSAR members. The reasons for developing 
consensus recommendations for EHD cancer and the 
first draft of statements to be included in the KSAR 
recommendations were presented at this meeting. An open 
discussion followed, and all KSAR members commented 
on each statement and the approach used to develop the 
consensus recommendations.
Amendment of Key Questions 
Statements were refined after the annual KSAR member 
meeting, followed by offline and online group meetings. 
Duplicated or redundant items were deleted or merged, and 
items deemed essential for the imaging evaluation of EHD 
cancer were maintained. Finally, 13 key questions with 24 
statements were chosen. 
Development of a Structured Reporting Form
Imaging studies are essential for initial decisions on 
patients with EHD cancer by radiologists. Although most 
radiologists currently do freestyle dictation to report 
imaging findings, it is limited by inter-reader variability, 
non-standardized descriptive terms, and possible omission 
of key findings, among others. Therefore, there is an 
increasing clinical need for structured reporting forms. 
Several societies have suggested structured reporting 
forms for pancreas cancer and rectal cancer (5, 9-11). 
However, no structured reporting forms have been published 
for EHD cancer, from the perspective of radiologists, 
with special emphasis on consistent terminology and 
image interpretation. Therefore, the KSAR study group 
for EHD cancer was determined to develop a structured 
reporting form for EHD cancer based on key questions and 
corresponding recommendation statements. 
Agreement Voting
After the key questions and statements were finalized, a 
consensus voting for all statements was held at the KSAR 
annual organ-based meeting on July 20, 2019. Before 
voting, participants were asked about their experience in 
biliary imaging, and only the results of those who had more 
than two years of experience were used for the analysis. 
The six-point modified Delphi method was used to collect 
the opinions of the participants. The participants replied 
to each statement using one of six choices: “strongly 
agree,” “agree with minor reservations,” “agree with major 
reservations,” “disagree with minor reservations,” “disagree 
with major reservations,” and “strongly disagree” (7). If 
more than 80% of the participants with more than 2 years 
of experience in biliary imaging chose “strongly agree” or 
“agree with minor reservations” for a given statement, it 
was considered to have reached consensus. Additionally, 
two issues on the structured reporting form were heavily 
debated within the KSAR study group before the annual 
meeting, and participants voted on their inclusion in the 
consensus recommendations.
Determination of Evidence Level
After a consensus was reached on all statements, 
relevant literature was reviewed again by the KSAR study 
group for EHD cancer, and the evidence level of each 
statement was graded based on the criteria of the Oxford 




Among the KSAR members who voted on each statement 
(mean: n = 79; range: 74–91), approximately 90% (n = 71; 
range: 67–79) had more than two years of experience in 
biliary imaging. After voting, 23 of 24 statements reached 
consensus (Table 1). For the structured reporting form, the 
two heavily debated issues did not reach consensus, and 
they were not included in the final structured reporting 
form. The first issue, “Length of main portal vein (MPV) 
invasion should be included in the structured form,” got 
an agreement of 51.4%; thus, it was excluded from the 




Table 1. Consensus Key Questions and Recommendation Statements
Key Questions and Recommendation Statements Agreement Level
Section 1. Nomenclature and definition
KQ 1. What are the criteria for classifying perihilar bile duct cancer and distal bile duct cancer?
S1.  EHD cancer can be classified as perihilar bile duct cancer or distal bile duct cancer based on the insertion 
site of the cystic duct. 
89.9%
KQ 2. How is the gross morphology of EHD cancer categorized? 
S2.  EHD cancer can be classified into the mass-forming, periductal-infiltrating, or intraductal-growing type 
based on growth patterns.
92.5%
Section 2. Imaging technique 
KQ 3.  Which imaging modality is recommended for patients suspected of EHD cancer, and when do we perform an 
imaging study if biliary intervention is needed?
S3.  Contrast-enhanced CT and/or contrast-enhanced MRI with MRCP are recommended to evaluate EHD cancer. 100%
S4. Imaging studies are recommended before any biliary interventional procedure whenever possible. 98.6%
KQ 4. What is the optimal CT protocol to evaluate EHD cancer?
S5. Multiphase imaging, which includes the precontrast, arterial, and portal venous phase, is recommended. 97.1%
S6. A slice thickness of 3 mm or less is recommended. 95.7%
S7.  Multiplanar reconstruction can aid the evaluation of relationships between EHD cancer and adjacent 
structures. 
98.6%
S8. Including the pelvis in at least one phase is recommended. 85.9%
KQ 5. Which MR sequences are needed to evaluate bile duct cancer?
S9.  T1-weighted images, T2-weighted and heavily T2-weighted images, MRCP, and contrast-enhanced dynamic 
images are recommended as MR sequences for bile duct cancer. 
97.3%
S10.  DWIs can help radiologists characterize bile duct lesions and detect extra-bile duct lesions. 89.7%
Section 3. Cancer evaluation 
KQ 6. Which imaging features indicate the presence of EHD cancer?
S11.  On contrast-enhanced CT or MRI, EHD cancer is indicated by irregular ductal wall thickening with upstream 
ductal dilatation, hyper-enhancement of the ductal wall relative to the liver, and/or obliteration of the 
lumen by an intraductal soft-tissue mass or thickened ductal wall. 
100%
S12.  On cholangiography, EHD cancer is indicated by the abrupt and/or irregular narrowing of the bile duct 
and irregularly shaped filling defects within the lumen. 
94.5%
KQ 7. How is the biliary tree classified when evaluating the longitudinal extent of EHD cancer?
S13.  Longitudinal involvement of EHD cancer can be assessed by classifying the presence/absence of tumor 
involvement in the right secondary confluence, right hepatic duct, primary confluence, left hepatic duct, 
left secondary confluence, common hepatic duct, suprapancreatic common bile duct, and intrapancreatic 
common bile duct. 
89.0%
S14.  The Bismuth-Corlette classification is recommended for the imaging assessment of bile duct involvement in 
perihilar bile duct cancer. 
97.3%
S15.  Proximal and distal extensions of perihilar bile duct cancer and proximal extensions of distal bile duct 
cancer are included in the imaging assessment of bile duct involvement. 
95.8%
KQ 8. How do we evaluate tumor vascular invasion on MDCT and MRI for EHD cancer? 
S16.  The hepatic artery, PV, and their branches as well as variant hepatic vessels should be evaluated for the 
presence of tumor invasion, depending on the anatomic location of the EHD cancer.
97.2%
S17.  Tumor vascular invasion is indicated by the tumor encasement of vessels, vessel deformity, occlusion, or 
tumor thrombus. 
92.6%
S18.  The degree of tumor-vessel contact is classified as no contact (preserved tumor-vessel fat plane), abutment 
(tumor involvement up to 50% of the vessel circumference), or encasement (tumor involvement more than 
50% of the vessel circumference).
95.7%
KQ 9. How do we evaluate LN metastasis in EHD cancer?
S19.  LNs are considered suspicious for metastatic involvement if they are greater than 1 cm along the short 
axis or have abnormal round morphology, heterogeneous enhancement, or central necrosis. 
92.9%
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important in some patients because a shorter invasion of 
MPV is advantageous for vascular reconstruction. However, 
it is challenging to measure MPV invasion accurately and 
consistently with routine axial and coronal reconstructed 
images. Moreover, in perihilar bile duct cancer, the invasion 
site of portal vein (PV) (ipsilateral/contralateral PV or MPV) 
is more important than the length. This may account for the 
exclusion of this item after it did not reach a consensus.
Subsequently, the final assessment of resectability was 
excluded from the structured reporting form. The statement, 
“Final assessment (resectability) should be included in the 
structured reporting form,” was agreed to by only 45.5%. 
To determine the resectability of EHD cancer, factors such 
as tumor extent, major vascular invasion, vascular or biliary 
anatomy, ability to reconstruct vessels, and future remnant 
liver volume need to be considered. Furthermore, decisions 
regarding tumor resectability may vary between surgeons 
and institutions without established criteria. Therefore, 
we concluded that it would be better not to include a 
standardized resectability assessment in the structured 
reporting form for EHD cancer.
Section 1. Nomenclature and Definition
KQ 1. What Are the Criteria for Classifying Perihilar Bile 
Duct Cancer and Distal Bile Duct Cancer?
Statement 1: EHD cancer can be classified as perihilar or 
distal based on the insertion site of the cystic duct (agreement 
level, 89.9%; evidence level, not applicable [n/a]).
The EHD is composed of the right extrahepatic duct, left 
extrahepatic duct, common hepatic duct, and common bile 
duct. Based on the cystic duct insertion site, the EHD can 
be subdivided into the perihilar area, which includes the 
right/left extrahepatic duct and the common hepatic duct, 
and the distal bile duct, which extends from the confluence 
of the cystic and common hepatic ducts to the ampulla of 
Vater (excluding the ampulla itself) (Fig. 1) (3, 14-16). 
EHD cancers originating from these two compartments 
are marked by various names: ‘hilar cholangiocarcinoma’ 
and ‘distal cholangiocarcinoma’ in National Comprehensive 
Cancer Network (NCCN) guidelines version 2.2019 (17), 
‘perihilar (proximal) cholangiocarcinoma’ and ‘distal bile 












Fig. 1. Anatomy of the EHD. EHD = extrahepatic bile duct
Table 1. Consensus Key Questions and Recommendation Statements (Continued)
Key Questions and Recommendation Statements Agreement Level
KQ 10. How do we evaluate distant metastasis in EHD cancer? 
S20.  MRI or 18F-FDG PET-CT is recommended to evaluate indeterminate or suspicious findings for distant 
metastasis on CT. 
92.6%
KQ 11. How do we assess the resectability of EHD cancer beyond the tumor staging/extent?
S21.  The future remnant liver volume and biliary/vascular anatomic variations need to be evaluated to 
determine the resectability of perihilar bile duct cancer. 
98.5%
S22. A multidisciplinary team consultation is recommended when deciding or assessing resectability. 91.7%
Section 4. Tumor response
KQ 12.  How do we evaluate treatment response through imaging after chemotherapy for patients with EHD 
cancer? 
S23.  Contrast-enhanced CT or contrast-enhanced MRI with MRCP according to the RECIST criteria is 
recommended. 
90.5%
CT = computed tomography, DWI = diffusion-weighted image, EHD = extrahepatic bile duct, KQ = key questions, LN = lymph node, MDCT = 
multidetector CT, MRCP = MR cholangiopancreatography, MRI = magnetic resonance imaging, PET = positron emission tomography, PV = 




on Cancer (AJCC) cancer staging manual (18), or ‘perihilar 
bile duct cancer’ and ‘distal extrahepatic bile duct cancer’ 
in the National Cancer Institute’s dictionary (15). The KSAR 
study group for EHD cancer discussed and agreed to use the 
terms ‘perihilar bile duct cancer’ and ‘distal bile duct cancer’ 
throughout the consensus recommendations, as these 
terms were intuitive and consistent for distinguishing the 
two parts of the EHD. EHD cancer is classified into these 
two categories because surgical techniques and surgical 
fields differ significantly between them. Furthermore, the 
T staging of tumors is also different, probably because the 
distribution of smooth muscles differs with location (19). 
The KSAR study group for EHD cancer also discussed how 
to establish a reference point for classifying the perihilar 
area and distal bile duct. According to previous studies, 
only 51–75% of cystic duct insertion sites are located in 
the middle third of the EHD (20, 21). Therefore, the KSAR 
members debated on whether dividing the perihilar area 
and the distal bile duct by the cystic duct insertion site was 
appropriate even when the cystic duct insertion site was 
not located in the middle of the EHD. Although new criteria 
were suggested, the KSAR study group for EHD cancer finally 
agreed to follow traditional standards, because the location 
of the cystic duct insertion site is not of clinical importance 
for treatment plans, and creating a new reference point 
can also create controversy. Perihilar bile duct cancer can 
extend into the intrahepatic bile duct or even the liver 
parenchyma, and EHD cancer may involve both the perihilar 
area and distal bile duct. In this case, the location of the 
tumor epicenter can be a reference point for categorization. 
However, describing the area of tumor involvement is more 
important because treatment plans are mainly determined 
based on tumor extent. 
KQ 2. How is the Gross Morphology of Extrahepatic Bile 
Duct Cancer Categorized? 
Statement 2: EHD cancer can be classified into the mass-
forming, periductal-infiltrating, or intraductal-growing 
type based on growth patterns (agreement level, 92.5%; 
evidence level, n/a). 
Because the gross morphology of EHD cancer can 
present with different imaging findings and tumor 
biology, descriptions of the gross tumor morphology can 
help in determining treatment plans and prognosis (22). 
Various terminologies have been suggested for the gross 
morphology of EHD cancer, such as mass-forming/nodular/
small fibrous nodules, periductal infiltrating/flat/sclerosing/
segmental stenosis, and intraductal growing/papillary or 
papillary growth (22, 23). The KSAR study group for EHD 
cancer aimed at determining appropriate terms that were 
intuitive, representative, and familiar to radiologists, and it 
recommended the mass-forming, periductal-infiltrating, and 
intraductal-growing type to classify the gross morphology 
of EHD cancer (Fig. 2) (22, 24). EHD cancer usually presents 
as the periductal-infiltrating type or intraductal-growing 
type. The periductal-infiltrating type spreads longitudinally 
through the periductal or perineural connective tissue 
and lymphatics even with intact mucosa, whereas the 
intraductal-growing type spreads superficially along the 
mucosa. Lymph node (LN) metastasis is more common and 
the periductal-infiltrating type shows a worse prognosis 
than the intraductal-growing type (22). Sometimes, EHD 
cancer can also present as a mixed type with two or more 
gross morphologies.
Section 2. Imaging Technique 
KQ 3. Which Imaging Modality is Recommended for 
Patients Suspected with Extrahepatic Bile Duct Cancer, 
and When Do We Perform an Imaging Study If Biliary 
Intervention Is Needed?
Statement 3: Contrast-enhanced CT and/or contrast-
enhanced MRI with MR cholangiopancreatography (MRCP) 
are recommended to evaluate EHD cancer (agreement level, 
100%; evidence level, IV).
Statement 4: Imaging studies are recommended before 
any biliary interventional procedure whenever possible 
(agreement level, 98.6%; evidence level, IV).
With recent advances in multidetector CT (MDCT) 
technology, CT provides rapid temporal resolution as well 
as high spatial resolution. Therefore, contrast-enhanced 
abdominopelvic CT is recommended when staging malignant 
diseases. In regards to EHD cancer, CT could facilitate the 
assessment of the extent of the primary EHD cancer and 
the relationship between the tumor and adjacent vascular 
structures, including the hepatic artery and PV, which is 
very important for tumor resectability. CT also provides 
information on distant metastases such as liver or distant 
LN metastasis and/or peritoneal seeding. Thus, contrast-
enhanced abdominopelvic CT has been regarded as the 
initial and standard imaging modality for patients suspected 
of EHD cancer (25-28). Contrast-enhanced MR has been 
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regarded as an alternative imaging modality to contrast-
enhanced CT for malignant diseases; however, it may be the 
initial imaging modality for patients who are hypersensitive 
to iodinated contrast media. In addition, MRCP can 
provide detailed information about the bile duct anatomy 
as well as the extent of EHD cancer. Several studies have 
Fig. 2. Gross morphology of EHD cancer. 
A, B. Mass-forming type: (A) on T1-weighted axial image, an enhancing nodular mass is noted within the CBD; (B) on T2-weighted coronal image, a 
nodular lesion is seen (arrow) within the distal CBD with upstream bile duct dilatation. C, D. Periductal-infiltrating type: (C) contrast-enhanced T1-
weighted axial image shows circumferential bile duct wall thickening with luminal narrowing at the EHD (arrow); (D) on MRCP, segmental narrowing 
(arrow) with upstream biliary dilatation is seen at the distal EHD. E, F. Intraductal-growing type: (E) on T1-weighted axial image, a polypoid mass 
(arrowheads) is seen within the EHD; (F) on MRCP, multiple polypoid lesions (arrowheads) are seen within the EHD. These polypoid tumors involved 
the right secondary confluence of the bile duct (Bismuth-Corette type IIIA) while extending into the intra-pancreatic common bile duct. CBD = 










reported that contrast-enhanced MR with MRCP can provide 
diagnostic accuracy that is comparable to that of contrast-
enhanced abdominopelvic CT with direct cholangiography 
when assessing the longitudinal tumor extent, vascular 
involvement, and tumor resectability of EHD cancer (29, 
30). It is also important to distinguish distal bile duct 
cancer from pancreatic cancer because chemotherapy 
regimens and prognoses differ, especially in unresectable 
cases. MRI with MRCP may help in ascertaining the origin of 
periampullary cancer (31). Hence, we recommend contrast-
enhanced CT and/or contrast-enhanced MR with MRCP to 
evaluate EHD cancer. 
Patients with EHD cancer usually present with jaundice due 
to bile duct obstruction, and a substantial portion of EHD 
cancer patients suffer from cholangitis and biliary sepsis as 
bile flow is blocked off. When biliary infections result from 
EHD cancer, an endoscopic or percutaneous biliary drainage 
procedure has to be urgently performed. However, biliary 
interventions such as the insertion of drain catheters can 
cause inflammatory changes in the bile duct. This can mimic 
tumor involvement and negatively affect the diagnostic 
performance of imaging studies that assess the extent of 
EHD cancer (32, 33). Taking this into consideration, we 
recommend imaging studies before any biliary interventional 
procedures whenever possible. However, no studies have 
accurately evaluated how biliary drainage procedures 
affect the diagnostic performance of imaging studies for 
assessing the tumor extent of EHD cancer. Additionally, no 
data has conclusively demonstrated the extent of reduction 
in diagnostic accuracy after biliary drainage procedures. 
The effect of biliary drainage procedures on the diagnostic 
performance of imaging studies for EHD cancer should be 
evaluated in a future study. 
KQ 4. What is the Optimal CT Protocol for Evaluating 
Extrahepatic Bile Duct Cancer?
Statement 5: Multiphase imaging, which includes 
the precontrast, arterial, and portal venous phase, is 
recommended (agreement level, 97.1%; evidence level, IV). 
Statement 6: A slice thickness of 3 mm or less is 
recommended (agreement level, 95.7%; evidence level, V).
Statement 7: Multiplanar reconstruction can aid the 
evaluation of relationships between EHD cancer and adjacent 
structures (agreement level, 98.6%; evidence level, IV). 
Statement 8: Including the pelvis in at least one phase is 
recommended (agreement level, 85.9%; evidence level, V). 
Multiphase images with contrast enhancement are 
usually obtained to evaluate EHD cancer (34). By acquiring 
multiphase images before and after the administration 
of contrast media, it is possible to adequately evaluate 
radio-opaque stones, vascular structures, and abdominal 
organs (35). Precontrast images help clinicians to detect 
intraductal stones and differentiate them from tumors 
(26, 28). Although some studies showed that routine 
acquisition of the arterial phase is not necessary for the 
detection and evaluation of EHD cancer and its extent 
(36, 37), the AJCC guidelines recommend that dynamic 
imaging be performed during the arterial and portal venous 
phases (1). The arterial phase is useful for enhancing 
the conspicuity of the distal bile duct cancer against the 
background. The portal venous phase is useful for judging 
the extrapancreatic extent of the distal bile duct cancer 
and detecting liver metastases (1). The delayed phase, 
which is usually observed 3–5 minutes after the injection 
of contrast agent, is not commonly acquired for EHD cancer 
(8). Detailed imaging findings of EHD cancer are described 
in Key Question 6 and its statements.
Thin-section imaging is recommended for EHD cancer 
(1, 8, 38, 39). No studies have conducted a head-to-head 
comparison between thin- and thick-section CT imaging to 
evaluate EHD cancer. Several studies use CT images with a 
slice thickness between 1.5 and 3 mm to distinguish benign 
papillary strictures from malignant ampullary tumors or 
determine the resectability of EHD cancers (40-43). The 
AJCC guidelines suggest 2- to 3-mm thicknesses for thin-
section CT imaging (1). Thus, we recommend a CT slice 
thickness of 3 mm or less.
Although axial CT is useful for evaluating biliary 
trees, cross-sectional images have limited value in 
demonstrating complex anatomical relationships. In this 
regard, multiplanar reformation (MPR) images are better 
at demonstrating the relationships between tumors and 
adjacent structures (28, 40, 41, 44-49). Longitudinal and 
vertical extensions of tumors can be identified with MPR 
images (49-52). MPR images can also help radiologists 
to assess vascular invasion of the primary tumor (49, 53, 
54). Curved planar reformation along the course of specific 
anatomic structures such as bile ducts and vessels is also 
useful when evaluating the longitudinal extent of the bile 
duct tumor (55-57). 
MDCT should facilitate the assessment of distant 
metastases in addition to the primary EHD tumor (1, 28, 
38). Peritoneum and LNs are among the most common 
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metastatic sites in both perihilar and distal bile duct 
cancers (1, 38, 41). Hence, MDCT that involves the 
abdomen and pelvis at initial staging is recommended to 
detect distant metastases such as peritoneal seeding, as 
this knowledge is critical for appropriate treatment plans 
and prognostic predictions. 
KQ 5. Which MR Sequences Are Needed to Evaluate Bile 
Duct Cancer?
Statement 9: T1-weighted, T2-weighted and heavily T2-
weighted, MRCP, and contrast-enhanced dynamic images 
are recommended as MR sequences for bile duct cancer 
(agreement level, 97.3%; evidence level, IV).
Statement 10: Diffusion-weighted images (DWIs) may 
help radiologists characterize bile duct lesions and detect 
extra-bile duct lesions (agreement level, 89.7%; evidence 
level, IV).
To evaluate EHD cancer, precontrast images should always 
include cross-sectional T2-weighted and T1-weighted 
sequences as well as heavily two-dimensional (2D) and/or 
three-dimensional (3D) T2-weighted MRCP, which has been 
accepted as an effective imaging modality for demonstrating 
the presence and level of biliary obstruction (58). 3D MRCP 
has superior image quality and ductal conspicuity than 
2D MRCP, although no significant difference was observed 
when evaluating tumor extent (59). When gadolinium-based 
contrast agents are used, multiphasic dynamic fat-saturated 
3D gradient-echo T1-weighted imaging (T1WI), involving 
the arterial and portal venous phases, is recommended. 
For hepatobiliary agent (HBA)-enhanced MRI, T2-weighted 
sequences and DWI can be performed after contrast-
enhanced dynamic phases to shorten examination times 
(60-63). However, heavily T2-weighted MRCP should be 
performed before the contrast agent is excreted into the 
biliary tree (60, 64). With higher concentrations of contrast 
agent in the biliary ductal system, the signal intensity of 
the bile appears darker on T2-weighted images (T2WIs) 
owing to the T2-shortening effect (64). 
DWI, typically using 0 to 100 sec/mm2 and 800 to 
1000 sec/mm2 for low and high b values, respectively, 
can provide additional information for patients with EHD 
cancer. The application of a 3T MRI system and parallel 
imaging techniques to DWI can enhance the signal-to-
noise ratio and lesion-to-liver contrast by improving image 
quality (65, 66). Some studies have reported that adding 
DWI to conventional MRI shows a high sensitivity for bile 
duct cancer (67), and it helps differentiate benign from 
malignant bile duct strictures (68, 69). DWI may also 
facilitate the evaluation of tumor extent and liver invasion 
as well as help differentiate liver metastases from biliary 
abscesses (70-73). 
Section 3. Cancer Evaluation 
KQ 6. Which Imaging Features Indicate the Presence of 
Extrahepatic Bile Duct Cancer?
Statement 11: On contrast-enhanced CT or MRI, EHD 
cancer is indicated by irregular ductal wall thickening with 
upstream ductal dilatation, hyper-enhancement of the 
ductal wall relative to the liver, and/or obliteration of the 
lumen by an intraductal soft-tissue mass or thickened ductal 
wall (agreement level, 100%; evidence level, III). 
Statement 12: On cholangiography, EHD cancer is 
indicated by the abrupt and/or irregular narrowing of the 
bile duct and irregularly shaped filling defects within the 
lumen (agreement level, 94.5%; evidence level, III).
On cross-sectional imaging and cholangiography, scar-
like fibrosis and/or intraductal tumors can result in irregular 
ductal wall thickening, luminal narrowing, and luminal 
obliteration, causing upstream bile duct dilatation (28, 74-
76). EHD tumors show increased enhancement to the liver 
on the arterial and/or portal venous phase; fibrosis and 
scirrhous tissue are better visualized on later phases (76, 
77). EHD cancer also more commonly presents with thicker 
bile duct wall, longer involved segment, luminal irregularity, 
asymmetric narrowing, and high signal intensity on DWI, 
compared to benign strictures (68, 78, 79). However, these 
features are also found in benign biliary diseases, including 
but not restricted to primary sclerosing cholangitis, AIDS-
related cholangiopathy, immunoglobulin G4-related 
sclerosing cholangitis, recurrent pyogenic cholangitis, and 
ischemic cholangitis (80). Thus, further histologic evidence 
is often required to confirm the diagnosis of bile duct 
abnormalities.
KQ 7. How Is the Biliary Tree Classified When Evaluating 
the Longitudinal Extent of Extrahepatic Bile Duct Cancer?
Statement 13: Longitudinal involvement of EHD cancer can 
be assessed by classifying the presence/absence of tumor 
involvement in the right secondary confluence, right hepatic 
duct, primary confluence, left hepatic duct, left secondary 




bile duct, and intrapancreatic common bile duct (agreement 
level, 89.0%; evidence level, V).
Statement 14: The Bismuth-Corlette classification is 
recommended for the imaging assessment of bile duct 
involvement in perihilar bile duct cancer (agreement level, 
97.3%; evidence level, V).
Statement 15: Proximal and distal extensions of perihilar 
bile duct cancers and proximal extensions of distal bile duct 
cancers are included in the imaging assessment for bile duct 
involvement (agreement level, 95.8%; evidence level, V).
Various terminologies have been proposed to describe 
the longitudinal extent of bile duct cancers. The modified 
Bismuth-Corlette classification is one of the most widely 
accepted systems, which uses primary confluence and right 
or left secondary confluence to describe tumor extent (81, 
82). The Bismuth-Corlette system defines the longitudinal 
extent of the tumor relative to the biliary confluences, which 
may roughly yield the estimated extent of surgery (81, 83). 
However, the applicability of the system is limited by biliary 
variation, and the potential resectability or scope of surgery 
may vary even among patients with the same Bismuth-
Corlette type (82, 84). Therefore, when reporting Bismuth-
Corlette classifications, the anatomic variation of the bile 
duct should be described in detail as well, if present.
The longitudinal extent of the tumor dictates the type 
of curative surgery, such as pancreaticoduodenectomy, 
hepatopancreaticoduodenectomy, hepatobiliary resection, 
or segmental bile duct resection, to be performed 
(83, 85, 86). Hepatobiliary resection, with or without 
pancreaticoduodenectomy, is regarded as the standard 
curative surgery for perihilar bile duct cancer (83). 
Hepatopancreaticoduodenectomy is a challenging procedure 
with high morbidity and mortality rates, but it gives 
patients a chance for long-term survival when curative 
resection is feasible. Thus, an accurate description of the 
proximal and distal extent of the perihilar bile duct cancer 
as well as the proximal extent of the distal bile duct cancer 
may help in determining appropriate treatment. 
In retrospective studies, the accuracy of enhanced CT for 
the longitudinal tumor extent ranged from 75–96% (29, 
87-90). In a meta-analysis, the pooled accuracy for CT was 
86% (25). MR cholangiography showed a similar accuracy 
of 71–80% (91-93), and adding enhanced MRI increased 
accuracy to 87–93.3% (29, 92). However, imaging studies 
may underestimate the longitudinal extent of the tumor; 
microscopic tumors that spread through the mucosa or 
submucosa are unnoticeable on imaging, although this 
results in positive resection margins (94). 
KQ 8. How Do We Evaluate Tumor Vascular Invasion on 
MDCT and MRI for Extrahepatic Bile Duct Cancer?
Statement 16: The hepatic artery and PV, as well as 
their branches, and the variant hepatic vessels should be 
evaluated for tumor invasion, depending on the anatomic 
location of the EHD cancer (agreement level, 97.2%; 
evidence level, V).
Statement 17: Tumor vascular invasion is indicated 
by the tumor encasement of vessels, vessel deformity, 
occlusion, or tumor thrombus (agreement level, 92.6%; 
evidence level, III).
Statement 18: The degree of tumor-vessel contact is 
classified as no contact (preserved tumor-vessel fat plane), 
abutment (tumor involvement up to 50% of the vessel 
circumference), or encasement (tumor involvement more 
than 50% of the vessel circumference) (agreement level, 
95.7%; evidence level, V).
The evaluation of tumor vascular invasion is crucial when 
determining the resectability of EHD cancer, especially for 
perihilar bile duct cancer. In a previous meta-analysis (25), 
the pooled sensitivity and specificity of MDCT for assessing 
the vascular invasion of perihilar bile duct cancer was 89% 
(95% confidence interval [CI], 80–94%) and 92% (95% 
CI, 85–96%), respectively, for PV invasion, and 84% (95% 
CI, 63–94%) and 93% (95% CI, 69–99%), respectively, for 
hepatic artery invasion. 
Tumor vascular invasion on MDCT and MRI is determined 
by the degree of tumor contact with vessels, vessel 
deformity, and vessel occlusion or tumor thrombus (Fig. 
3). We recommend classifying the degree of tumor-vessel 
contact as no contact (preserved tumor-vessel fat plane), 
abutment (tumor involvement up to 50% of the vessel 
circumference), or encasement (tumor involvement more 
than 50% of the vessel circumference), following the NCCN 
guidelines for pancreatic cancer (95) (Fig. 3). 
Although previous studies evaluated imaging criteria for 
the vascular invasion of EHD cancer (25, 29, 41, 49, 53, 
88, 96-100), all of them were retrospective with small to 
moderate study populations. Another point of consideration 
is that perivascular infiltration may not always be a 
tumor; it may be an inflammatory infiltration. In most 
of these cases, surgery was not performed and, hence, 
perivascular infiltration was not pathologically confirmed. 
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Despite the low evidence level of past study findings, they 
consistently demonstrated that vessel encasement in EHD 
cancer strongly indicates vessel invasion, with reported 
specificities of 93–97% and sensitivities of 70–88% (29, 41, 
88, 96, 99, 100). On the other hand, the absence of tumor-
vessel contact may reliably rule out vessel invasion. The 
negative predictive value of this finding for excluding tumor 
invasion was reported as 93–100% (49, 53). However, 
tumor abutment is considered inconclusive. Previous 
studies reported that tumor abutment of vessels resulted 
in a sensitivity of 100%, with only a moderate specificity 
of 77–90% for detecting vessel invasion (49, 53). Thus, 
radiologists cannot arrive at a confident diagnosis of 
vessel invasion using only tumor abutment. However, this 
finding should be reported in radiologic reports for doctors 
to consider when planning surgery or considering surgical 
resectability through multidisciplinary discussions.
KQ 9. How Do We Evaluate Lymph Node Metastasis in 
Extrahepatic Bile Duct Cancer?
Statement 19: LNs are considered suspicious for 
metastatic involvement if they are greater than 1 cm 
Fig. 3. Degree of tumor-vessel contact. 
(A) No contact: a fat plane is preserved between tumor and vessel. (B) Abutment: tumor involves up to 50% of the vessel circumference, (C-F) 
vascular invasion. (C) Encasement: tumor involves more than 50% of the vessel circumference, (D) occlusion, (E) contour deformity, (F) tumor 










along the short axis or have abnormal round morphology, 
heterogeneous enhancement, or central necrosis (agreement 
level, 92.9%; evidence level, III).
Only a few reports on the diagnostic accuracy of LN 
metastasis in EHD cancer are available (25, 101, 102). 
Previous studies have used various combinations of 
characteristics such as a short diameter of 1 cm, abnormal 
round morphology, heterogeneous enhancement, or central 
necrosis to diagnose LN metastasis. A meta-analysis for 
hilar bile duct cancer yielded a sensitivity of 61% and a 
specificity of 88% for detecting LN metastases (25). In 
terms of LN size, a cutoff of 1 cm for the short diameter 
is the diagnostic criterion for LN metastasis for other 
malignancies; metastatic LNs are significantly larger than 
their non-metastatic counterparts. However, a previous 
study reported that only 23% of LNs larger than 1 cm were 
associated with metastatic cells, and 10% of LNs smaller 
than 1 cm harbored metastatic cells (102). Furthermore, 
enlarged reactive regional LNs are more frequent in 
EHD cancer than in other malignancies because of the 
accompanying obstructive cholangitis. Therefore, the size 
criterion should be used with other imaging criteria to 
provide a reliable diagnosis of LN metastasis on imaging 
studies (102). Combinations of the size criterion and 
round morphology or internal heterogeneity demonstrated 
an increased positive predictive value for LN metastasis, 
compared with the size criterion alone (101). However, the 
low prevalence of such characteristic LNs is a limitation 
of this approach. For the preoperative assessment of LN 
metastasis, similar limitations have been reported for other 
malignancies as well (103, 104). Although imaging studies 
do not show enough accuracy to assess LN metastasis, 
LNs greater than 1 cm along the short axis with abnormal 
round morphology, heterogeneous enhancement, or central 
necrosis are more likely to be metastatic. According to 
findings from recent studies, 18F-fluorodeoxyglucose 
(18F-FDG) positron emission tomography (PET)-CT may 
help radiologists in differentiating LN metastasis from its 
differentials (105, 106).
KQ 10. How Do We Evaluate Distant Metastasis in 
Extrahepatic Bile Duct Cancer?
Statement 20: MRI or 18F-FDG PET-CT is recommended for 
evaluating indeterminate or suspicious findings of distant 
metastasis on CT (agreement level, 92.6%; evidence level, V).
The liver is the most common (11.9–23.2%) site of 
metastasis, followed by the lung (2.7–5.8%) and distant 
LNs (3.0–4.4%) (107). The peritoneum is also a common 
site of metastasis; however, the exact prevalence of 
metastasis is unknown. Diagnosing liver metastasis is a 
challenge in EHD cancer patients because small biliary 
abscesses frequently coexist due to biliary obstruction. 
The findings from previous studies suggest that patchy 
parenchymal enhancement, arterial rim enhancement 
persistent through portal venous phase and perilesional 
hyperemia on CT and MR, and size discrepancy between 
T1WI and T2WI as well as T1WI and the hepatobiliary phase 
on MR are indicative of biliary abscess rather than liver 
metastasis (108, 109). Short-term follow-up with imaging 
can also help radiologists to assess lesional size changes. 
An ultrasound-guided biopsy may also aid differential 
diagnosis if technically feasible.
The extent and location of regional LNs are defined 
differently for perihilar bile duct cancer and distal bile 
duct cancer. Hilar, cystic duct, choledochal, portal, 
hepatic arterial, and posterior pancreaticoduodenal LNs 
are classified as regional LNs in perihilar bile duct cancer, 
whereas the common bile duct, hepatic artery, the posterior 
and anterior pancreaticoduodenal, and the right lateral 
wall of the superior mesenteric artery LNs are classified as 
regional LNs in distal bile duct cancer (18). The differential 
diagnoses of reactive and metastatic LNs are described in 
detail in Statement 19.
Peritoneal metastases are frequently underestimated on CT 
(110, 111). In a meta-analysis of peritoneal metastases in 
all cancers, 18F-FDG PET-CT demonstrated good sensitivity 
(87%) and specificity (92%) for the detection of peritoneal 
metastasis (112).
KQ 11. How Do We Assess the Resectability of Extrahepatic 
Bile Duct Cancer beyond the Tumor Staging/Extent?
Statement 21: The future remnant liver volume as well as 
biliary and vascular anatomic variations has to be evaluated 
to determine the resectability of perihilar bile duct cancer 
(agreement level, 98.5%; evidence level, VI).
Statement 22: A multidisciplinary team consultation is 
recommended when deciding or assessing resectability 
(agreement level, 91.7%; evidence level, n/a).
For perihilar bile duct cancer, preoperative assessment of 
biliary and vascular anatomy variations and tumor extent to 
the intrahepatic bile duct is important because resectability 
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depends on hilar biliary and vascular anatomy (84, 113). For 
example, the anterior and posterior sectional branches of the 
right hepatic duct drain directly into the main hepatic duct 
at a 20% frequency; hence, this case may be misdiagnosed as 
the Bismuth classification type IV, which is an unresectable 
case, when the hilar tumor involves the right anterior and 
posterior hepatic ducts with a segmental involvement of 
the left side (84, 113). However, if diagnosed properly, 
radical resection with an extended left hepatectomy may be 
preferred as a curative treatment. Various anatomic variations 
may exist, but the important consideration is whether blood 
flow to the remaining liver can be preserved. The availability 
of surgical techniques, such as vascular reconstruction, 
should also be considered (114).
Because extended hepatic resections are usually required 
for curative treatment, it is important to estimate the 
future remnant liver volume in patients with perihilar 
bile duct cancer (84). According to previous studies, a 
future remnant liver volume of > 25–30% is considered a 
safe cutoff for patients with healthy liver parenchyma, 
whereas > 40% is considered in patients with compromised 
livers such as cholestatic livers (115, 116). CT and MRI 
are standard techniques for assessing future remnant liver 
volume. 
The diagnosis and management of EHD cancer are 
challenging, and it requires skilled experts. As diagnosis and 
management of EHD cancer are complex and the availability 
of surgical resection or liver transplantation depends on 
surgical expertise, an optimal assessment and decision 
on resectability require a multidisciplinary collaboration 
between hepatobiliary surgeons, endoscopists, radiologists, 
medical oncologists, and pathologists (117, 118).
Section 4. Tumor Response
KQ 12. How Do We Evaluate Treatment Response 
through Imaging after Chemotherapy for Patients with 
Extrahepatic Bile Duct Cancer?
Statements 23: Contrast-enhanced CT or MRI with MRCP, 
according to the response evaluation criteria in solid 
tumors (RECIST), is recommended (agreement level, 90.5%; 
evidence level, V).
According to previous literature, most researchers use 
their follow-up protocols for patients with EHD cancer 
placed on chemotherapy (119-143). There is currently no 
“standard” follow-up strategy for assessing patients after 
chemotherapy for EHD cancer with imaging modalities. 
However, most studies on clinical trials for new drugs have 
used the RECIST criteria to assess tumor response (121, 
122, 125, 126, 128-135, 140-143). 
We recommend contrast-enhanced CT and contrast-
enhanced MRI with MRCP as imaging modalities for 
assessing tumor response using the RECIST criteria. A 
universal follow-up schedule has not been discussed 
in these guidelines; schedules should be determined 
by clinicians according to chemotherapy regimen, 
complications such as biliary obstruction or infection, and 
disease stage. 
The Key Questions and Statement Which Did 
Not Reach Consensus
KQ. Which Type of MRI Contrast Agent Can Be Used to 
Evaluate Bile Duct Cancer?
Statement: For bile duct cancer, extracellular agents (ECAs) 
are preferred over gadoxetate disodium, among MRI contrast 
agents (agreement level, 61.4%; evidence level, IV).
This statement on the optimal contrast media for EHD 
cancer did not reach a consensus because there was not 
enough data to support the diagnostic superiority of MRI 
with ECA (ECA-MRI) over MRI with gadoxetate disodium 
(HBA-MRI) for EHD cancer. So far, only a few publications 
have evaluated the clinical applications of HBA-MRI when 
assessing EHD cancer (72, 144).
There are several drawbacks to using HBA-MRI in the 
preoperative evaluation of bile duct cancer. First, there 
are concerns about transient motion artifacts that appear 
during the arterial phase (145, 146) and less vascular 
enhancement due to the lower amount of administered 
gadoxetate disodium (0.025 mmol/kg vs. 0.1 mmol/kg 
for extracellular gadolinium chelates) (147). Second, the 
uptake of HBA into hepatocytes and its excretion into the 
biliary tree can be hindered by high bilirubin related to 
biliary obstruction (64, 148). In addition, the increased 
signal intensity of the liver may hinder the evaluation of 
bile duct wall enhancement. Third, the cost of performing 
HBA-MRI is higher than that of ECA-MRI (149, 150). The 
statement may not have reached a consensus because of 
these reasons. The advantages and disadvantages of HBA-
MRI should be understood before it is used to evaluate bile 
duct cancer, and without further guidelines, an MRI contrast 




Table 2. Suggested Structured Report Form for EHD Cancer
1. Imaging quality
□ Appropriate
□ Not appropriate, but diagnosable               □ Not appropriate, hard to diagnose
Additional description:
2. Location
□ Perihilar bile duct cancer                          □ Distal bile duct cancer
Additional description:
3. Biliary intervention
□ Absent         
□ Performed, but not disturbing diagnosis      □ Performed with disturbing diagnosis 
4. Bile duct evaluation 
1) Bile duct involvement
□ Right secondary confluence                    □ Left secondary confluence
□ Right hepatic duct                                □ Left hepatic duct
□ Primary confluence                               □ Common hepatic duct
□ Suprapancreatic common bile duct          □ Intra-pancreatic common bile duct 





□ Right posterior duct inserted to the left hepatic duct
□ Right posterior duct inserted to the common bile duct
□ Other (please specify):
3) Bismuth classification
□ I          □ II          □ IIIa          □ IIIb          □ IV
4) Gross morphology (based on the dominant component)
□ Mass-forming (maximum size:     cm)








□ Replaced or □ accessory right hepatic artery from _________ 
□ Replaced or □ accessory left hepatic artery from _________
□ Replaced common hepatic artery from _________
□ Other (please specify)




□ PV trifurcation 
□ Right posterior PV as the first branch of MPV
□ Other (please specify): 
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This structured reporting form was developed to provide a 
common reporting form for EHD that could be readily used 
in daily clinical practice. If a structured reporting form is 
complicated, it will be inconvenient to incorporate it into 
clinical practice, and it will eventually be shunned by the 
medical community. Therefore, a structured reporting form 
for EHD should be as simple as possible; however, it should 
include essential items such as bile duct involvement, vessel 
invasion, regional LN metastasis, and distant metastasis 
evaluation, while noting whether the EHD cancer is located 
on the perihilar bile duct or distal bile duct (Table 2). The 
starting questions of the structured reporting form should 
Table 2. Suggested Structured Report Form for EHD Cancer (Continued)
5. Vessel evaluation
3) Evaluation of tumor vascular invasion
Artery □ No contact □ Abutment □ Invasion
Right hepatic artery □ No contact □ Abutment □ Invasion
Left hepatic artery □ No contact □ Abutment □ Invasion
Proper hepatic artery □ No contact □ Abutment □ Invasion
Common hepatic artery □ No contact □ Abutment □ Invasion
Celiac axis □ No contact □ Abutment □ Invasion
Superior mesenteric artery □ No contact □ Abutment □ Invasion
Other (please specify) □ No contact □ Abutment □ Invasion
Vein □ No contact □ Abutment □ Invasion
Right PV □ No contact □ Abutment □ Invasion
Left PV □ No contact □ Abutment □ Invasion
MPV □ No contact □ Abutment □ Invasion
Superior mesenteric vein □ No contact □ Abutment □ Invasion
Other (please specify) □ No contact □ Abutment □ Invasion
Additional description:
6. Regional LN metastasis evaluation
□ Absent          □ Indeterminate*          □ Present
*LN (≤ 1 cm along short axis) with suspicious findings of metastasis (abnormal round morphology, heterogeneous enhancement, 
central necrosis, increased 18F-FDG uptake) or LNs (> 1 cm) without suspicious findings of metastasis.
Additional description:
7. Distant metastasis evaluation 
1) Liver lesion
□ Absent          □ Indeterminate (specify location)          □ Present (specify location)
2) Peritoneal carcinomatosis
□ Absent          □ Indeterminate*          □ Present 
*Consider diagnostic laparoscopy.
3) Distant LNs
□ Absent          □ Indeterminate (specify location)          □ Present (specify location)
4) Other (organ involved: __________)
□ Absent          □ Indeterminate          □ Present 
Additional description:




be on imaging quality and if image quality is not sufficient 
for accurate diagnosis, re-examinations or additional 
examinations are recommended. Biliary intervention may 
also affect the diagnostic accuracy of imaging, so biliary 
intervention procedures should also be recorded. Essential 
items are listed under each section title and users can select 
the items that correspond to their observations by marking 
the matching checkboxes. If multiple items are observed, 
users can select all of the concerned items in that particular 
section. Items with low incidence such as certain variations 
of blood vessels or bile ducts have to be filled out directly. 
Additional descriptions can be recorded under each section 
(in the ‘additional description’) if required. This structured 
reporting form focuses on the evaluation of initially 
diagnosed EHD cancer before treatment and does not intend 
to evaluate treatment response. We hope to validate the 
diagnostic performances and inter-reader agreements of this 
structured reporting form for EHD cancer in future studies.
SUMMARY
Twelve key questions and 23 statements on the imaging 
analysis of EHD cancer were confirmed through consensus at 
several meetings. A structured reporting form was developed 
based on these key questions and recommendation 
statements, which included essential items to be evaluated 
such as bile duct involvement, vessel invasion, and LN and 
distant metastasis. Although the evidence levels of most 
recommendations were low due to insufficient research, the 
consensus recommendations and the structured reporting 
form were developed to summarize existing findings and 
clarify future research topics. Furthermore, the proposed 
structured reporting form can be used to accumulate 
standardized data progressively; based on newly collected 
data, guidelines may be revised when answers are found to 
questions that are currently unresolved. This will increase 
the evidence levels of the current recommendations.
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